Haematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant
haematological diseases. Despite continuous improvements in pre-and post-transplantation …

Although significant advances have been made in the biologic understanding of graft-versus-
host disease (GVHD) and its treatment options, GVHD remains the single most challenging …

As the use of hematopoietic stem cell transplantation (HSCT) has become a more
widespread and effective treatment for hematological malignant and non-malignant …

ABSTRACT Introduction Extracorporeal Photopheresis (ECP) may be considered the unique
large-scale cell therapy currently available. It is currently employed mainly as second-line …

Chronic graft-versus-host disease (GVHD) is the most important cause of late morbidity and
mortality in recipients of allogeneic blood and marrow transplantation. Despite increased …

Graft-versus-host disease (GVHD) remains a major challenge for progress in allogeneic
hematopoietic cell transplantation. Steroids continue to be the most effective firstline therapy …

Extracorporeal photopheresis (ECP) is an autologous cell therapy that is widely used for the
treatment of T cell-mediated diseases. ECP has been FDA-approved for the treatment of …

Acute and chronic graft-versus-host disease (GVHD) remain major obstacles for successful
allogeneic hematopoietic cell transplantation. Extracorporeal photopheresis (ECP) …

Graft-versus-host disease (GVHD) is a major cause of mortality and morbidity following
allogeneic hematopoietic stem cell transplantation. Extracorporeal photopheresis (ECP) …

Extracorporeal photopheresis (ECP), a personalized cellular immunotherapy, constitutes a
promising treatment for steroid-refractory/-resistant graft-versus-host disease (SR-GvHD) …